Abstract:A recombinant human parathyroid hormone fragment, Pro-Pro-hPTH(1-34), with molecular weight of 4311.46 was acquired through gene engineering. It was then isolated and purified. The homogeneity of this fragment was characterized by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), high performance liquid chromatography(HPLC), isoelectronic focusing (IEF) electrophoresis and mass spectrometry(MS) methods. Its isoelectric point is 8.0 which was determined by IEF. It was found that the hormone fragment significantly induced calcium increment as compared to the control group (P<0.001) in Parsons's Chicken Assay, an established bioassay for the evaluation of the PTH effect. After the 3-month-old ovariectomized (OVXed) rats, the OVXed rat is one of the two models required by the U.S. Food and Drug Administration for the preclinical assessment of drugs for treating osteoporosis [DeLuca PP, Dani BA. Skeletal effects of parathyroid hormone (1-34) in ovariectomized rats with or without concurrent administration of salmon calcitonin. Am Assoc Pharm Sci 2001;3(4):E27 [1]]. Sprague-Dawley rats were fed for 14 weeks, daily subcutaneous injections of Pro-Pro-hPTH(1-34) for 16 weeks (0.4, 0.6 or 0.9 nmol/100 g body weight), reduced the ovariectomy (OVX)-triggered mass loss of vertebral trabecular bone. The mean Bone Material Density (BMD) increased to 29.2-34.5% in 3-month-old OVXed rats compared to control-vehicle group (P<0.001) and increased to 17.5-22.3% compared to sham-operated groups (P<0.01). In short, A recombinant Pro-Pro-hPTH(1-34) was harvested in purified form and its physico-chemical characterization was determined. It showed significantly enhanced activity upon two typical models for PTH fragments. It can increase the mineral density of vertebral trabecular bone just as synthetic hPTH(1-34), and the functional activity of Pro-Pro-hPTH(1-34) should be due to the removing of Pro-Pro- by Dipeptidyl peptidase IV (DPPIV). This study opened out a simplified method which was cheaper, faster than the conventional one for producing active hPTH fragment, and its applied prospect would be good; Furthermore, it may open up our own path in finding new methods for post-processing of gene-engineering product.

Study of treating effect to osteoporosis of recombinant human parathyroid hormone related protein 1-86

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

Therapeutic Effect of a Novel Recombinant Human Parathyroid Hormone Related Peptide on Osteoporosis in Ovariectomized Rats

Therapeutic Effect of Recombinant Human Parathyroid Hormone(1-34) on Osteoporosis of Ovariectomized Rats

Impacts of the N-terminal Fragment Analog of Human Parathyroid Hormone on Structure, Composition and Biomechanics of Bone

Molecular Mechanisms of Rhpth(1-34) Influence on Osteoporosis in Ovariectomized Rats

Therapeutic Effect of Rhpth (1-34) on Glucocorticoid-Induced Osteoporosis in Rats

Effect of recombinant human parathyroid hormone on bone fracture healing in the rat observed by micro-CT

Treatment Study of Distal Femur for Parathyroid Hormone (1–34) and Β-Tricalcium Phosphate on Bone Formation in Critical-Sized Defects in Osteopenic Rats

Pharmacological Effects of a Recombinant Hpth(1-34) Derived Peptide on Ovariectomized Rats.

A Novel Human Parathyroid Hormone (1-34) Analog for the Treatment of Osteoporosis

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis

Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.

Effects of Bone Formation on Culture Osteoblasts with Rhpth(1-34) in Vitro

Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension.

Enhancing Bone Regeneration and Osseointegration using rhPTH(1-34) and Dimeric R25CPTH(1-34) in an Osteoporotic Beagle Model

Method of Parathyroid Hormone Acting on Bone Metabolism--related Genes Expression of Old Rats' Bone Marrow Cells

Effect of Bone Peptide on Functions of Bone Formation and Bone Resorption in Osteoporotic Model Rats

Observation on Efficacy and Safety of Recombinant Human Parathyroid Hormone 1-34 with Caltrate D in Primary Osteoporosis

Enhancing bone regeneration and osseointegration using rhPTH(1-34) and dimeric R25C PTH(1-34) in an osteoporotic beagle model

Efficacy of recombinant human parathyroid hormone 1-34(rhPTH1-34) in post-menopausal osteoporosis